Section of Cardiology Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA.
Curr Atheroscler Rep. 2021 Jan 3;23(1):4. doi: 10.1007/s11883-020-00900-5.
This review highlights late-breaking science presented at the American Heart Association Scientific Session 2020 that demonstrated advancements in preventative cardiology and introduced novel treatment approaches for the management of chronic kidney disease, type 2 diabetes, and/or heart failure.
The studies reviewed include clinical trials that assessed the use of omecamtiv in the treatment of heart failure with reduced heart failure (GALACTIC-HF); effects of sotagliflozin in patients with diabetes and recent heart failure exacerbation; cardiovascular outcomes with the use of omega-3 carboxylic acids in patients with high vascular risk and atherogenic dyslipidemia (STRENGTH) and omega-3 fatty acids in elderly patients with recent myocardial infarction (OMEMI); efficacy and safety of evinacumab in patients with refractory hypercholesterolemia; and the use of coronary computed tomography angiography for the assessment of suspected acute coronary syndrome. In addition, we review the results of the International Polycaps Study (TIPS-3) on the use of a polypill for the primary prevention of cardiovascular disease in intermediate-risk people. Finally, we discuss the SAMSON trial-a three-arm-N-of-1 trial-to identify the root cause of the symptoms contributing to patient nonadherence to statin therapy. The studies presented at the American Heart Association Scientific Session 2020 represent remarkable contributions in the field of cardiovascular disease and prevention.
本次综述重点介绍了美国心脏协会 2020 科学会议上发表的最新科学进展，这些进展展示了在预防心脏病学方面的进展，并为慢性肾脏病、2 型糖尿病和/或心力衰竭的管理引入了新的治疗方法。
回顾的研究包括临床试验，评估了 omecamtiv 在射血分数降低的心力衰竭（GALACTIC-HF）中的治疗作用；sotagliflozin 在糖尿病和近期心力衰竭恶化患者中的作用；高血管风险和动脉粥样硬化性血脂异常患者使用 ω-3 羧酸（STRENGTH）和近期心肌梗死后老年患者使用 ω-3 脂肪酸的心血管结局（OMEMI）；evinacumab 在难治性高胆固醇血症患者中的疗效和安全性；以及冠状动脉计算机断层血管造影在疑似急性冠状动脉综合征评估中的应用。此外，我们还回顾了国际多胶囊研究（TIPS-3）关于在中危人群中使用复方药进行心血管疾病一级预防的结果。最后，我们讨论了 SAMSON 试验——一项三臂自身对照 1 例试验——以确定导致患者不遵他汀类药物治疗的症状的根本原因。美国心脏协会 2020 科学会议上发表的研究代表了在心血管疾病和预防领域的杰出贡献。
